Roffman Miller Associates Inc. PA Buys 2,953 Shares of Johnson & Johnson $JNJ

Roffman Miller Associates Inc. PA boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% during the 2nd quarter, Holdings Channel.com reports. The firm owned 266,371 shares of the company’s stock after buying an additional 2,953 shares during the quarter. Johnson & Johnson accounts for about 2.4% of Roffman Miller Associates Inc. PA’s holdings, making the stock its 15th largest position. Roffman Miller Associates Inc. PA’s holdings in Johnson & Johnson were worth $40,688,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Nuveen LLC bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $1,369,188,000. Bank of New York Mellon Corp lifted its holdings in Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares in the last quarter. Pacer Advisors Inc. boosted its position in shares of Johnson & Johnson by 1,382.0% in the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock worth $502,509,000 after purchasing an additional 2,825,626 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Johnson & Johnson by 159.6% in the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock worth $635,327,000 after purchasing an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $401,420,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $186.24 on Tuesday. The company has a market cap of $448.71 billion, a price-to-earnings ratio of 17.98, a PEG ratio of 2.19 and a beta of 0.40. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48. The stock’s 50 day simple moving average is $183.43 and its two-hundred day simple moving average is $167.96. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on JNJ. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $209.00 target price on shares of Johnson & Johnson in a report on Friday, October 10th. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a research report on Monday, October 20th. Bank of America boosted their price target on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a report on Wednesday, October 15th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday. Finally, Argus set a $210.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 15th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.